Alvopem^® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

References

• Cancer IAfRo. Islamic republic of Iran fact sheets: Global cancer inventory; 2021. Available from: https://gco.iarc.fr/today/fact-sheets-populations.
   Google Scholar
• Salehiniya H, Bahadori M, Ghanizadeh G, Raei MEpidemiological study of lung cancer in Iran: a systematic reviewIran J Public Health2022512306317
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal AGlobal cancer statistics, 2012CA Cancer J Clin201565287108
   PubMed Web of Science ®Google Scholar
• Tsao AS, Wistuba I, Roth JA, Kindler HLMalignant pleural mesotheliomaJ Clin Oncol200927122081
   PubMed Web of Science ®Google Scholar
• Presley CJ, Reynolds CH, Langer CJCaring for the older population with advanced lung cancerAm Soc Clin Oncol Educ Book201737587596
   PubMedGoogle Scholar
• Brims FEpidemiology and clinical aspects of malignant pleural mesotheliomaCancers202113164194
   PubMed Web of Science ®Google Scholar
• Howlander N, Garshell J, et al. SEER Cancer Statistics Review 1975–2012, (ed April 2016). hesda, MD: National Cancer Institute,Bet 2015.
   Google Scholar
• Lexicomp. (n.d.). Pemetrexed: Drug information. UpToDate. Retrieved September 5, from https://www.uptodate.com/contents/pemetrexed-drug.
   Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol2003211426362644
   PubMed Web of Science ®Google Scholar
• Manegold C, editor Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Seminars in oncology; 2003: Elsevier.
   Google Scholar
• National Cancer Institute: FDA Approval for Pemetrexed Disodium [cited 2021 Oct 17].
   Google Scholar
• Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al.Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesotheliomaLung Cancer20117217377
   PubMed Web of Science ®Google Scholar
• Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson A, Nowak A, et al.Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Ann Oncol2022332129142
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol2008262135433551
   PubMed Web of Science ®Google Scholar
• Cohen MH, Justice R, Pazdur RApproval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancerOncologist2009149930935
   PubMed Web of Science ®Google Scholar
• Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli CPemetrexed in the treatment of advanced non-squamous lung cancerLung Cancer2009662141149
   PubMed Web of Science ®Google Scholar
• Healthcare Professional Website. ALIMTA.com. Eli Lilly and Company. Archived from the original on 7 January 2009. Retrieved 1 December 2008 [cited 2021 Oct 20].
   Google Scholar
• Di B-S, Wei K-P, Tian J-H, Xiao X-J, Li Y, Zhang X-H, et al.Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysisAsian Pac J Cancer Prev201415834193424
   PubMedGoogle Scholar
• Okubo S, Kobayashi N, Taketsuna M, Kaneko N, Enatsu S, Nishiuma SSafety and effectiveness of pemetrexed in patients with non-small cell lung cancer in Japan-analysis of post-marketing surveillanceGan Kagaku ryoho Cancer Chemother2014414475481
   PubMedGoogle Scholar
• Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, et al.Randomized phase III study of continuation maintenance bevacizumab with or without pemetrexed in advanced nonsquamous non-small-cell lung cancer: COMPASS (WJOG5610L)J Clin Oncol2020388793803
   PubMed Web of Science ®Google Scholar
• Xiao H-Q, Tian R-H, Zhang Z-H, Du K-Q, Ni Y-MEfficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysisOnco Targets Ther201691471
   PubMed Web of Science ®Google Scholar
• Nanoalvand pharmaceutical company, https://www.nanoalvand.com/products/detail/Pemetrexed/115/view/. Accessed 13 Oct 2021.
   Google Scholar
• Machin D, Campbell MJ, Tan SB, Tan SHSample size tables for clinical studies2011USAWiley
   Google Scholar
• Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al.Pemetrexed combined with Oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialClin Cancer Res2005112690696
   PubMed Web of Science ®Google Scholar
• Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, et al.Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trialLung Cancer2013802185190
   PubMed Web of Science ®Google Scholar
• Fuld ADDK, Rigas JRPemetrexed in advanced non-small-cell lung cancerExpert Opin Pharmacother20101113871402
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, et al.Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02–2006 randomized phase II study and pooled analysis with the NVALT7 trialJ Clin Oncol2012303645014507
   PubMed Web of Science ®Google Scholar
• Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, et al.Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesotheliomaJpn J Clin Oncol2019491110041008
   PubMed Web of Science ®Google Scholar
• Li J, Chi Y, Cao G, Zhao J, An T, Wu M, et al.Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world settingJ Thorac Dis202113318131821
   PubMed Web of Science ®Google Scholar
• Khosravi A, Salimi B, Esfahani-Monfared Z, Seifi S, Mirtavoos-Mahyari HA Phase IV efficacy study of formeta plus carboplatin as first-line treatment of advanced non-squamous, non-small cell lung cancer in iran: an affordable price with clinical benefitAsian Pacific J Cancer Prevent APJCP201819102973
   PubMedGoogle Scholar